Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Froggatt

Showing results (271-280 of 277) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 277 results.
JAMA Internal Medicine|November 12, 2019
Evaluation of a Palliative Care Program for Nursing Homes in 7 Countries: The PACE Cluster-Randomized Clinical TrialLieve Van den Block, Elisabeth Honinx, Lara Pivodic, et al.
BMC Palliative Care|March 14, 2018
Integrating palliative care in long-term care facilities across Europe (PACE): protocol of a cluster randomized controlled trial of the 'PACE Steps to Success' intervention in seven countriesTinne Smets, Bregje B D Onwuteaka-Philipsen, Rose Miranda, et al.
Nature Communications|October 24, 2025
Mechanobiologically-optimized non-resorbable artificial bone for patient-matched scaffold-guided bone regenerationJonathan R Clark, D S Abdullah Al Maruf, Eva Tomaskovic-Crook, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2020
Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 <i>in vitro</i>Nir Drayman, Krysten A Jones, Saara-Anne Azizi, et al.
Nature Microbiology|August 22, 2025
SARS-CoV-2 infection induces pro-fibrotic and pro-thrombotic foam cell formationDiana M Battaglia, Claire E Post, Wenbo Yao, et al.
Science (New York, N.Y.)|July 21, 2021
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2Nir Drayman, Jennifer K DeMarco, Krysten A Jones, et al.
Hemasphere|February 26, 2026
Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UKAndrea Kuhnl, Amy A Kirkwood, Michael Northend, et al.
Pageof 28

Showing results (271-280 of 277) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 277 results.
JAMA Internal Medicine|November 12, 2019
Evaluation of a Palliative Care Program for Nursing Homes in 7 Countries: The PACE Cluster-Randomized Clinical TrialLieve Van den Block, Elisabeth Honinx, Lara Pivodic, et al.
BMC Palliative Care|March 14, 2018
Integrating palliative care in long-term care facilities across Europe (PACE): protocol of a cluster randomized controlled trial of the 'PACE Steps to Success' intervention in seven countriesTinne Smets, Bregje B D Onwuteaka-Philipsen, Rose Miranda, et al.
Nature Communications|October 24, 2025
Mechanobiologically-optimized non-resorbable artificial bone for patient-matched scaffold-guided bone regenerationJonathan R Clark, D S Abdullah Al Maruf, Eva Tomaskovic-Crook, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2020
Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 <i>in vitro</i>Nir Drayman, Krysten A Jones, Saara-Anne Azizi, et al.
Nature Microbiology|August 22, 2025
SARS-CoV-2 infection induces pro-fibrotic and pro-thrombotic foam cell formationDiana M Battaglia, Claire E Post, Wenbo Yao, et al.
Science (New York, N.Y.)|July 21, 2021
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2Nir Drayman, Jennifer K DeMarco, Krysten A Jones, et al.
Hemasphere|February 26, 2026
Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UKAndrea Kuhnl, Amy A Kirkwood, Michael Northend, et al.
Pageof 28